Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence
Evidence-based review of maropitant (Cerenia) for vomiting in dogs and cats — canine motion sickness, feline CKD, dexmedetomidine-induced emesis comparators, and the emerging visceral-analgesia role — with NK1 mechanism and FDA label facts.
Read →Telmisartan (Semintra) for Proteinuria and Hypertension in Cats with CKD
Evergreen clinical reference on telmisartan (Semintra) for feline CKD proteinuria and systemic hypertension: the pivotal 224-cat RCT vs benazepril, FDA/EMA indications, ARB pharmacology and PK, contested aldosterone-suppression-test data, 2026 circulating-RAAS findings, and IRIS 2023 staging, phosphate, and monitoring guidance for licensed DVMs.
Read →Oclacitinib (Apoquel) for Canine Atopic Dermatitis: JAK Inhibition and Clinical Evidence
Oclacitinib (Apoquel) for canine atopic dermatitis: 24-hour onset RCT data, head-to-head vs prednisolone, ciclosporin, and ilunocitinib, 10-year safety and neoplasia evidence, JAK1 mechanism, combination protocols, and monitoring.
Read →Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
Grapiprant (Galliprant) for canine osteoarthritis: EP4 receptor antagonism mechanism, the pivotal JVIM field study (48.1% vs 31.3% success), FDA/EMA approval, meloxicam and firocoxib comparators, RCVS-appraised evidence strength, and multimodal use in young dogs and cats.
Read →Capromorelin (Entyce & Elura) for Appetite Stimulation: Evidence and Clinical Use in Dogs and Cats
The clinician's evidence hub for capromorelin — the first ghrelin (GHS-R1a) receptor agonist appetite stimulant. Covers Entyce dosing and canine field-study efficacy, the Elura feline CKD pivotal RCT (+6.81% body-weight treatment effect), comparators, adverse effects, and cardiac/glycemic precautions.
Read →Mirtazapine Transdermal Ointment (Mirataz) for Feline Weight Loss
FDA-approved mirtazapine transdermal ointment (Mirataz) for feline weight loss: pivotal field-study results, receptor mechanism, and lymphoma, CKD, and owner-adherence evidence. Includes dosing, the MAOI contraindication, and comparator guidance.
Read →Gabapentin for Pre-Visit Feline Anxiety: Evidence and Clinical Use
The evergreen clinical reference on gabapentin in cats: randomized and systematic-review evidence for pre-visit anxiolysis, the ~40% ataxia rate and 8-hour resolution window, cardiovascular safety, the pregabalin comparison, and the emerging atopic-dermatitis adjunct signal.
Read →Frunevetmab (Solensia) for Feline Osteoarthritis: Efficacy and Real-World Safety
A clinician's evidence hub on frunevetmab (Solensia) for feline OA pain: the Gruen 2021 pivotal RCT and real-world quality-of-life data on efficacy, plus RCT and FDA-database adverse-event signals (predominantly dermatological, with unconfirmed neurological and joint signals).
Read →Verdinexor (Laverdia) for Canine Lymphoma: Mechanism and Evidence
Verdinexor (Laverdia-CA1), an oral XPO1/nuclear-export inhibitor for canine lymphoma: mechanism, an 8-dog cutaneous T-cell pilot, and combination data.
Read →Tasipimidine (Tessie) for Noise Aversion and Separation Anxiety in Dogs
First FDA-approved drug for both noise aversion and separation anxiety in dogs. Alpha-2 agonist mechanism, oral solution, May 2026 approval.
Read →Librela (Bedinvetmab) in Dogs: Efficacy, Adverse Events & Monitoring
Librela (bedinvetmab) in dogs — side effects, the 2025 musculoskeletal/RPOA safety debate, efficacy vs meloxicam and grapiprant, contraindications, and monitoring. Cited for practitioners.
Read →Pregabalin for Chiari-like Malformation and Syringomyelia Pain in Dogs
Evidence summary on pregabalin for canine CM/SM neuropathic pain: a randomized placebo-controlled crossover study, disease course, and other options.
Read →